Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Receivables (2021 - 2025)

Historic Receivables for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to $352.1 million.

  • Apellis Pharmaceuticals' Receivables rose 2398.25% to $352.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.1 million, marking a year-over-year increase of 2398.25%. This contributed to the annual value of $269.5 million for FY2024, which is 2861.87% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Receivables stood at $352.1 million for Q3 2025, which was up 2398.25% from $220.1 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Receivables high stood at $352.1 million for Q3 2025, and its period low was $719000.0 during Q2 2021.
  • Moreover, its 5-year median value for Receivables was $142.7 million (2023), whereas its average is $140.1 million.
  • In the last 5 years, Apellis Pharmaceuticals' Receivables skyrocketed by 218482.93% in 2023 and then tumbled by 2875.11% in 2025.
  • Apellis Pharmaceuticals' Receivables (Quarter) stood at $10.1 million in 2021, then decreased by 9.24% to $9.2 million in 2022, then skyrocketed by 2184.83% to $209.5 million in 2023, then rose by 28.62% to $269.5 million in 2024, then skyrocketed by 30.66% to $352.1 million in 2025.
  • Its Receivables was $352.1 million in Q3 2025, compared to $220.1 million in Q2 2025 and $241.3 million in Q1 2025.